文献速递血液净化与透析水电解质与酸碱

终末期肾病两种磷酸盐目标试验(TARGET):一项随机对照试验

Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-05-26

在加拿大5个中心开展的随机对照试验,纳入已服用碳酸钙作为磷结合剂的血液透析患者,随机分为强化组(血磷目标2.33-4.66 mg/dl)或宽松组(6.20-7.75 mg/dl),通过剂量调整碳酸钙滴定26周。主要结局为血清磷酸盐从随机化到26周的变化差异。结果显示强化组血磷下降1.24 mg/dl(95%CI 0.75-1.74),组间高钙血症、低钙血症、甲状旁腺切除术或主要血管事件风险无统计学显著差异。

要点

  • 通过碳酸钙剂量滴定可安全实现并维持透析患者血磷浓度差异。
  • 强化降磷组与宽松组在高钙血症、低钙血症等风险上无显著差异。
  • 需大型试验确定更低血磷目标是否改善患者重要结局。

核心结论

  • 通过滴定碳酸钙可在血液透析患者中实现并维持血清磷酸盐浓度的差异。
  • 需要大型试验来确定以更低血清磷酸盐浓度为靶目标是否能改善患者重要结局。

研究设计与样本

  • 纳入已服用碳酸钙作为磷结合剂的 prevalent 血液透析患者,随机分配至强化磷目标组(2.33-4.66 mg/dl,即0.75-1.50 mmol/L)或宽松目标组(6.20-7.75 mg/dl,即2.00-2.50 mmol/L),通过剂量列线图滴定碳酸钙,持续26周。
  • 强化组53例,宽松组51例。
  • 主要结局为随机化至26周血清磷酸盐的变化差异。

主要发现

  • 26周时强化组元素钙每日剂量中位数(四分位距)为1800(1275-3000)mg,宽松组为0(0-500)mg。
  • 26周时强化组平均(标准差)血清磷酸盐为4.53(1.12)mg/dl(1.46 [0.36] mmol/L),宽松组为6.05(1.40)mg/dl(1.95 [0.45] mmol/L)。
  • 强化组血清磷酸盐较宽松组下降1.24(95%置信区间0.75至1.74)mg/dl(0.40 [95%置信区间0.24至0.56] mmol/L)。
  • 两组在高钙血症、低钙血症、甲状旁腺切除术或主要血管事件风险方面无统计学显著差异。

关键数值与推荐

  • 强化组血清磷酸盐目标:2.33-4.66 mg/dl(0.75-1.50 mmol/L)。
  • 宽松组血清磷酸盐目标:6.20-7.75 mg/dl(2.00-2.50 mmol/L)。

临床怎么用

  • 对于已服用碳酸钙的血液透析患者,可通过剂量滴定实现不同的血清磷酸盐目标。
  • 在缺乏大型试验证据前,强化降磷对患者重要结局的获益尚不明确。

局限性

  • 本研究为预试验,样本量较小(强化组53例,宽松组51例)。
  • 研究未评估患者重要结局的差异,仅报告中间指标。
  • 研究仅纳入已服用碳酸钙的血液透析患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Hyperphosphatemia is common among recipients of maintenance dialysis and is associated with a higher risk of mortality and cardiovascular events. A large randomized trial is needed to determine whether lowering phosphate concentrations with binders improves patient-important outcomes. To inform such an effort we conducted a pilot randomized controlled trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a randomized controlled trial of prevalent hemodialysis recipients already receiving calcium carbonate as a phosphate binder at five Canadian centers between March 31, 2014 and October 2, 2014. Participants were randomly allocated to 26 weeks of an intensive phosphate goal of 2.33-4.66 mg/dl (0.75-1.50 mmol/L) or a liberalized target of 6.20-7.75 mg/dl (2.00-2.50 mmol/L) by titrating calcium carbonate using a dosing nomogram. The primary outcome was the difference in the change in serum phosphate from randomization to 26 weeks. RESULTS: Fifty-three participants were randomized to the intensive group and 51 to the liberalized group. The median (interquartile range) daily dose of elemental calcium at 26 weeks was 1800 (1275-3000) mg in the intensive group, and 0 (0-500) mg in the liberalized group. The mean (SD) serum phosphate at 26 weeks was 4.53 (1.12) mg/dl (1.46 [0.36] mmol/L) in the intensive group and 6.05 (1.40) mg/dl (1.95 [0.45] mmol/L) in the liberalized group. Phosphate concentration in the intensive group declined by 1.24 (95% confidence interval, 0.75 to 1.74) mg/dl (0.40 [95% confidence interval, 0.24 to 0.56] mmol/L) compared with the liberalized group. There were no statistically significant differences between the two groups in the risk of hypercalcemia, hypocalcemia, parathyroidectomy, or major vascular events. CONCLUSIONS: It is feasible to achieve and maintain a difference in serum phosphate concentrations in hemodialysis recipients by titrating calcium carbonate. A large trial is needed to determine if targeting a lower serum phosphate concentration improves patient-important outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wald R, Rabbat CG, Girard L, et al. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2017. PMID: 28550080. doi:10.2215/CJN.10941016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。